Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imipenem: the first thienamycin antibiotic.

R J Williams1

  • 1Department of Medical Microbiology, London Hospital Medical College, UK.

Postgraduate Medical Journal
|January 1, 1986
PubMed
Summary

Imipenem shows broad-spectrum antibacterial activity against aerobes and anaerobes. Clinical trials indicate it is effective with minimal side effects, though in vitro studies suggest limited improvement against certain resistant bacteria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An outbreak of hantavirus pulmonary syndrome in western Paraguay.

The American journal of tropical medicine and hygiene·1997
Same author

Body dissatisfaction as a mediator of the relationship between dietary restraint and bulimic eating patterns.

Appetite·1997
Same author

Hantavirus transmission in the United States.

Emerging infectious diseases·1997
Same author

Reconstruction of the patellar tendon using a patella-quadriceps tendon autograft.

Orthopedics·1997
Same author

An intra-abdominal tumour.

Postgraduate medical journal·1997
Same author

Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils.

British journal of rheumatology·1997

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Imipenem represents a novel beta-lactam antibiotic.
  • It shares a mechanism of action with penicillins and cephalosporins.
  • Possesses broad-spectrum antibacterial properties against aerobic and anaerobic bacteria.

Purpose of the Study:

  • To evaluate the efficacy and safety of imipenem.
  • To assess its in vitro activity against challenging bacterial pathogens.
  • To compare imipenem's performance with existing antibacterial agents.

Main Methods:

  • In vitro susceptibility testing against various bacterial strains.
  • Clinical trial analysis of imipenem's therapeutic effects.
  • Evaluation of adverse events and toxicity profiles.

Main Results:

  • Imipenem demonstrates potent activity against a wide range of bacteria.
  • In vitro, it showed limited advantages over other agents for specific resistant organisms like Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and enterococci.
  • Clinical trials confirmed imipenem's efficacy in treating infections.

Conclusions:

  • Imipenem is an effective antibacterial agent with a broad spectrum of activity.
  • While in vitro data suggests limited improvement against certain resistant strains, clinical outcomes are favorable.
  • The antibiotic is well-tolerated, with no significant toxic side effects reported in trials.

Related Experiment Videos